中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Issue 6
Jun.  2010
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2010  >  26(6): 651-653

The effect of S-adenosyl-methionine treatment on drug-induced liver injury

  • Published Date: 2010-06-20
    Abstract
  • Objective To evaluate the therapeutic efficacy and safety of different dose S-adenosyl-L-methionine on drug-induced cholestasis liver injury and mixed liver injury.Methods a total of 66 patients suffered from drug-induced cholestasis liver injury and mixed liver injury were randomly divided into treatment group and control group.Furthermore, the treatment group was divided into 2 groups as treatment 1 group and treatment 2 group.The control group was treated with common therapy, while the treatment 1 group was treated with S-adenosyl-L-methionin up to 1 g/d as well as the treatment 2 group was treated with S-adenosyl-methionin up to 2 g/d.After 4 weeks of treatment, liver function was measured.Results The level of total bilirubin and alanine transaminase significantly decreased in the treatment group than the control group (P < 0.05) .Moreover, no adverse reactions were observed.Total bilirubin and alanine transarninase significantly decreased in treatment 2 group compared to treatment 1 group (P < 0.01) .Conclusion The therapeutic efficacy and safety of large dose S-adenosyl-L-methionin in treating drug-induced cholestasis liver injury and mixed liver injury is better compared to the common therapy.

     

    • FullText(HTML)
    • References(13)
  • [1]Bénichou C.Criteria of drug-induced liver disorders.Report of an international consensus meeting[J].J Hepatology, 1990, 11 (2) ∶272-276.
    [2]Danan G, Benichou C.Causality assessment of adverse reactions to drugs-I.A novel method based on the conclusions of international consensus meetings application to drug-induced liver injuries[J].J Clin Epidemiol, 1993, 46 (11) ∶1323-1330.
    [3]Ribalta J, Reyes H, Gonzalez MC.S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy:a randomized, double-blind, placebo-controlled study with negative results[J].Hepatology, 1991, 13 (6) ∶1084-1089.
    [4]Bogdanos DP, Dalekos GN.Enzymes as target antigens of liver specific autoimmunity:the case of cytochromes P450s[J].Curr Med Chem, 2008, 15 (22) ∶2285-2292.
    [5]Russmann S, Kullak-Ublick GA, Grattagliano I.Current concepts of mechanisms in drug-induced hepatotoxicity[J].Curr Med Chem, 2009, 16 (23) ∶3041-3053.
    [6]Murray KF, Hadzic N, Wirth S.Drug-related hepatotoxicity and acute liver failure[J].J Pediatr Gastroenterol Nutr, 2008, 47 (4) ∶395-405.
    [7]Uetrecht J.Immunoallergic drug-induced liver injury in humans[J].Semin Liver Dis, 2009, 29 (4) ∶383-392.
    [8]Andrade RJ, Robles M, Ulzurrun E.Drug-induced liver injury:insights from genetic studies[J].Pharmacogenomics, 2009, 10 (9) ∶1467-1487.
    [9]Tarantino G, Di Minno MN, Capone D.Drug-induced liver injury:is it somehow foreseeable[J].World J Gastroenterol, 2009, 15 (23) ∶2817-2833.
    [10]Bliven EE, Podewils LJ.The role of chronic hepatitis in isoniazid hepatotoxicity during treatment for latent tuberculosis infection[J].Int J Tuberc Lung Dis, 2009, 13 (9) ∶1054-1060.
    [11]Anderson GD.Gender differences in pharmacological response[J].Int Rev Neurobiol, 2008, 83∶1-10.
    [12]Tajiri K, Shimizu Y.Practical guidelines for diagnosis and early management of drug-induced liver injury[J].World J Gastroenterol, 2008, 14 (44) ∶6774-6785.
    [13]王雪明, 李楠, 魏荣.腺苷蛋氨酸治疗药物性肝损害疗效与血液中GSH变化关系[J].中国基层医药, 2002, 9 (6) ∶497-498.
    • Relative Articles

  • Relative Articles

    [1]Ren Yan, Zheng SuJun. Experience in clinical treatment of drug-induced liver injury:a case report[J]. Journal of Clinical Hepatology, 2017, 33(12): 2395-2396. doi: 10.3969/j.issn.1001-5256.2017.12.029
    [2]Liu ChengHai, Zhu ChunWu. Epidemic features, major causes, and diagnostic evaluation of herb-induced liver injury[J]. Journal of Clinical Hepatology, 2017, 33(5): 829-832. doi: 10.3969/j.issn.1001-5256.2017.05.007
    [3]Wang YueZhi, Zhang Yu. Research advances in drug- induced liver injury in the elderly[J]. Journal of Clinical Hepatology, 2016, 32(4): 821-824. doi: 10.3969/j.issn.1001-5256.2016.04.049
    [4]Yang Jun, Yu YaLi, Zheng ZhangQing. Clinical features of drug- induced liver injury and primary biliary cirrhosis: a comparative analysis[J]. Journal of Clinical Hepatology, 2016, 32(4): 728-731. doi: 10.3969/j.issn.1001-5256.2016.04.024
    [5]Shen ShuiYing, Wu Jun. Acute liver failure caused by antitubercular drugs: a report of one case[J]. Journal of Clinical Hepatology, 2015, 31(9): 1483-1484. doi: 10.3969/j.issn.1001-5256.2015.09.029
    [6]Drug-induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the management of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2015, 31(11): 1752-1769. doi: 10.3969/j.issn.1001-5256.2015.11.002
    [7]Qi YaBin, Qiu Ling, Jiang HongLi, Zhang Rui, Hu YuLin. Clinical characteristics of drug-induced liver injury: an analysis of 394 cases[J]. Journal of Clinical Hepatology, 2014, 30(5): 438-441. doi: 10.3969/j.issn.1001-5256.2014.05.014
    [8]Yu Zheng, Jia JiDong. Risk factors, diagnostic criteria, and drug discontinuation criteria for drug- induced liver injury[J]. Journal of Clinical Hepatology, 2013, 29(9): 674-677. doi: 10.3969/j.issn.1001-5256.2013.09.010
    [9]Hu XingWu, Qi ChangJin, Zhou HongXing. Therapeutic efficacy of ursodeoxycholic acid for drug-induced liver disease[J]. Journal of Clinical Hepatology, 2012, 28(9): 695-696.
    [10]Yu XiaoFang. Captopril-induced liver injury and considerations for hepatitis[J]. Journal of Clinical Hepatology, 2012, 28(7): 549-550.
    [11]Su HaiBin, Wang HuiFen. Clinical significance of drug-induced liver failure[J]. Journal of Clinical Hepatology, 2012, 28(10): 738-739+747.
    [12]Dai WeiJia, Lai RongTao, Wang Hui, Xie Qing, Tang WeiLiang, Zhuang Yan, Gui HongLian, Yu MinJie, Xie JingDong, Zhou HuiJuan. The analysis of clinical features and risk factors in 113 patients with drug-induced liver injury[J]. Journal of Clinical Hepatology, 2011, 27(10): 1058-1061+1065.
    [13]Wang ChunYan, Li Bing. One case of congenital hepatic fibrosis and hepatitis B virus infection and drug-induced liver injury[J]. Journal of Clinical Hepatology, 2011, 27(12): 1318-1319.
    [14]Zhou ShuYun, Cui Ying. The effect of ademetionine on patients with drug-induced cholestatic hepatitis[J]. Journal of Clinical Hepatology, 2010, 26(1): 69-71.
    [15]Yin Yan, Shi QuanDong, Liu Jing.

    Clinical observation of adenosylmethionine combined with compound salvia miltiorrhiza injection in the treatment of senile intrahepatic cholestasis

    [J]. Journal of Clinical Hepatology, 2009, 25(1): 54-55.
    [18]Zhang Pin, Huang YanQing, Wang XueFen, Gong ZuoJiong. Effects of s-adenosylmethionine on methionine metabolism and lipid peroxidation of liver from rats with ethanol-induced liver injury[J]. Journal of Clinical Hepatology, 2007, 23(1): 31-33.
    • Supplements(0)
    • Cited By
  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 4.9 %FULLTEXT: 4.9 %META: 89.2 %META: 89.2 %PDF: 5.9 %PDF: 5.9 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 8.4 %其他: 8.4 %其他: 1.9 %其他: 1.9 %Central District: 0.4 %Central District: 0.4 %Malaysia: 0.8 %Malaysia: 0.8 %[]: 1.5 %[]: 1.5 %上海: 3.4 %上海: 3.4 %中卫: 0.2 %中卫: 0.2 %伊斯坦布尔: 1.9 %伊斯坦布尔: 1.9 %伦敦: 0.4 %伦敦: 0.4 %佛山: 0.4 %佛山: 0.4 %保山: 0.2 %保山: 0.2 %加尔各答: 0.2 %加尔各答: 0.2 %北京: 5.9 %北京: 5.9 %南京: 0.4 %南京: 0.4 %南宁: 0.2 %南宁: 0.2 %厦门: 0.4 %厦门: 0.4 %吉林: 0.2 %吉林: 0.2 %吉隆坡: 0.4 %吉隆坡: 0.4 %基辅: 0.2 %基辅: 0.2 %大连: 0.2 %大连: 0.2 %孟买: 1.1 %孟买: 1.1 %张家口: 1.7 %张家口: 1.7 %德罕: 1.3 %德罕: 1.3 %慕尼黑: 0.2 %慕尼黑: 0.2 %成都: 0.2 %成都: 0.2 %新山: 0.2 %新山: 0.2 %新德里: 0.2 %新德里: 0.2 %曼谷: 0.2 %曼谷: 0.2 %杭州: 0.2 %杭州: 0.2 %武汉: 0.2 %武汉: 0.2 %沈阳: 0.2 %沈阳: 0.2 %法兰克福: 0.2 %法兰克福: 0.2 %海得拉巴: 0.6 %海得拉巴: 0.6 %深圳: 0.2 %深圳: 0.2 %漳州: 0.2 %漳州: 0.2 %班加罗尔: 0.8 %班加罗尔: 0.8 %石家庄: 0.2 %石家庄: 0.2 %福州: 0.4 %福州: 0.4 %罗奥尔凯埃: 0.6 %罗奥尔凯埃: 0.6 %芒廷维尤: 30.4 %芒廷维尤: 30.4 %芝加哥: 0.2 %芝加哥: 0.2 %苏州: 0.4 %苏州: 0.4 %莫斯科: 0.2 %莫斯科: 0.2 %葵涌: 0.4 %葵涌: 0.4 %西宁: 27.2 %西宁: 27.2 %西安: 0.6 %西安: 0.6 %诺沃克: 0.2 %诺沃克: 0.2 %赫梅利尼茨基: 1.3 %赫梅利尼茨基: 1.3 %金华: 0.2 %金华: 0.2 %长春: 0.4 %长春: 0.4 %长沙: 1.1 %长沙: 1.1 %阿菲永卡拉希萨尔: 0.2 %阿菲永卡拉希萨尔: 0.2 %黄冈: 0.2 %黄冈: 0.2 %其他其他Central DistrictMalaysia[]上海中卫伊斯坦布尔伦敦佛山保山加尔各答北京南京南宁厦门吉林吉隆坡基辅大连孟买张家口德罕慕尼黑成都新山新德里曼谷杭州武汉沈阳法兰克福海得拉巴深圳漳州班加罗尔石家庄福州罗奥尔凯埃芒廷维尤芝加哥苏州莫斯科葵涌西宁西安诺沃克赫梅利尼茨基金华长春长沙阿菲永卡拉希萨尔黄冈

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (422) PDF downloads(167) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2226]YesterdayPV[4110]TodayIP[1247]TodayPV[1877]Online[97]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return